NSABP Members' Area Password Protected - Access Limited to NSABP Participating Institutions Only NSABP Foundation, Inc. General NSABP Information Financial Conflicts of Interest Policy Contact the NSABP Employment Clinical Trials Information Clinical Trials Overview Protocol Chart Never Say Lost Treatment Trials Information Protocol B-51 Protocol B-52 Protocol B-53/S1207 Protocol B-55/BIG 6-13 Prevention Trials Information Protocol P-1 - BCPT Protocol P-2 - STAR To report problems, ask questions or make comments, please send e-mail to: Webmaster@nsabp.pitt.edu |
Protocol C-10 A Phase II Trial of 5-Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) Chemotherapy Plus Bevacizumab for Patients with Unresectable Stage IV Colon Cancer and a Synchronous Asymptomatic Primary Tumor Specific Aims Primary Aim To determine the rate of major morbidity for patients who are treated with mFOLFOX6 + bevacizumab without resection of the primary tumor. Major morbidity is defined as any event related to the intact primary tumor necessitating surgery or resulting in patient death. Secondary Aim Local Complications To determine the rate of specific events related to the intact primary tumor requiring hospitalization or a major intervention but not requiring surgery. Serious Adverse Events Related to Study Therapy To determine the rate of ≥ grade 3 toxicity as defined by the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0) that is related to study therapy prior to disease progression. To determine overall survival. |